About Peptidyl-prolyl cis-trans isomerase FKBP8
Peptidyl-prolyl cis-trans isomerase FKBP8 (FKBP8) is a protein
from Homo sapiens identified by UniProt accession
Q14318, 412 residues long.
MolForge cross-references it against 0 known binders and
93 disease associations.
Target properties
| Protein name | Peptidyl-prolyl cis-trans isomerase FKBP8 |
| UniProt accession | Q14318 |
| Gene | FKBP8 |
| Organism | Homo sapiens |
| Length | 412 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (93)
Diseases linked to this target (Open Targets).
- glioblastoma multiforme · score 0.23
- ovarian cancer · score 0.23
- breast adenocarcinoma · score 0.23
- spina bifida · score 0.19
- potassium measurement · score 0.18
- esophageal cancer · score 0.10
- glioblastoma · score 0.05
- microcephaly-cervical spine fusion anomalies syndrome · score 0.04
- Microcephaly - cervical spine fusion anomalies · score 0.04
- Hyperlipidemia · score 0.04
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q14318-F1 | alphafold | PREDICTED | 80.63 | — |
Amino-acid sequence (412 residues)
MASCAEPSEP SAPLPAGVPP LEDFEVLDGV EDAEGEEEEE EEEEEEDDLS ELPPLEDMGQ PPAEEAEQPG ALAREFLAAM EPEPAPAPAP EEWLDILGNG LLRKKTLVPG PPGSSRPVKG QVVTVHLQTS LENGTRVQEE PELVFTLGDC DVIQALDLSV PLMDVGETAM VTADSKYCYG PQGRSPYIPP HAALCLEVTL KTAVDGPDLE MLTGQERVAL ANRKRECGNA HYQRADFVLA ANSYDLAIKA ITSSAKVDMT FEEEAQLLQL KVKCLNNLAA SQLKLDHYRA ALRSCSLVLE HQPDNIKALF RKGKVLAQQG EYSEAIPILR AALKLEPSNK TIHAELSKLV KKHAAQRSTE TALYRKMLGN PSRLPAKCPG KGAWSIPWKW LFGATAVALG GVALSVVIAA RN
Explore Peptidyl-prolyl cis-trans isomerase FKBP8 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets